Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 1999

View Archived Issues

Proof-of-concept trial completed for Sheffield's MSI delivery system

Cell Therapeutics initiates phase II trial of Apra; phase I results presented at ASCO

NIH awards second SBIR to Structural Bioinformatics

Novel vaccine increases survival in melanoma patients

Endocyte and NCI enter vitamin-targeted anticancer therapy collaboration

Genmab acquires exclusive rights to IL-15 antibody patents

Mallinckrodt to acquire exclusive license to Palatin's LeuTech

Independent DSMB recommends conclusion of Remune phase III trial

Interneuron: Q2 1999 highlights

Avalide now available in U.S. for hypertension

Aronex updates stockholders at annual meeting

FDA allows LXR Biotechnology's IND for CP-Cardiosol

Microcide: Q1 1999 highlights

New use of RPR-102359 and related compounds as cytokine production inhibitors

Antiinflammatory/immunomodulatory agents in the Fujisawa pipeline

Inhibitors of Ras prenylation with bicyclic structure designed at Merck & Co.

VEGF TK inhibitors described by Merck for angiogenic ocular disorders

Potent and selective GABA-A receptor ligands under study at Neurogen

High-affinity ligands for the GABA-A benzodiazepine binding site patented by Ortho-McNeil

News from DDW: Antegren evaluated in patients with Crohn's disease, ulcerative colitis

Warner-Lambert presents new MMP inhibitors and their use

NT-3, a neurotrophic factor with gut motility-enhancing activity in humans

Leinamycin derivative selected by Kyowa Hakko for further development

Favorable pharmacokinetic, safety and efficacy profile for FMdC in phase I; phase II trials begin

Emtricitabine efficacy in HBV reported at Digestive Disease Week

Sinomenine/ciclosporin combination prolongs transplant survival in rat model

First proteasome inhibitor in clinical development profiled at oncology meeting

VasoCare therapy prevents ischemia-reperfusion injury-induced renal failure in dogs

Vitamin D analogue CD-483 has synergistic activity with classical immunosuppressants

Neurogen and Pfizer further extend obesity research program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...